Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma.

ABSTRACT:

Importance

Management of checkpoint inhibitor-induced immune-related adverse events (irAEs) is primarily based on expert opinion. Recent studies have suggested detrimental effects of anti-tumor necrosis factor on checkpoint-inhibitor efficacy.

Objective

To determine the association of toxic effect management with progression-free survival (PFS), overall survival (OS), and melanoma-specific survival (MSS) in patients with advanced melanoma treated with first-line ipilimumab-nivolumab combination therapy.

Design, setting, and participants

This population-based, multicenter cohort study included patients with advanced melanoma experiencing grade 3 and higher irAEs after treatment with first-line ipilimumab and nivolumab between 2015 and 2021. Data were collected from the

SUBMITTER: van Not OJ 

PROVIDER: S-EPMC9614679 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature